Medical application lowering A1c and improving T2DM drugs

Published Date: 02 Mar 2023

Patients with type 2 diabetes who used a smartphone app for cognitive behavioral therapy showed a significant decrease in A1c levels.

Read Full News

Latest News

The HCPFive: Top News for Healthcare Providers from the Week of 10/18

The HCPFive: Top News for Healthcare Providers from the Week of 10/18

Lutikizumab Improves HS Pain, Flares in Phase 3 INTREPID Study

Lutikizumab Improves HS Pain, Flares in Phase 3 INTREPID Study

Why Dermatologists Should Stay Involved in Advanced Cutaneous SCC Shannon C. Trotter, DO

Shannon C. Trotter, DO, FAOCD, discusses immunotherapy in advanced cutaneous squamous cell carcinoma and why dermatologists should stay involved.

Nonsurgical Skin Cancer Care and New Approvals, With Todd Schlesinger, MD

Nonsurgical Skin Cancer Care and New Approvals, With Todd Schlesinger, MD

Daxdilimab Improves Discoid Lupus in Phase 2, With Victoria Werth, MD Victoria Werth, MD

Both doses of the anti-ILT7 antibody daxdilimab reduced CLASI-A scores vs placebo at week 24 in moderate-to-severe, treatment-refractory discoid lupus.

5-Year ADlong Data on Lebrikizumab for Eczema, With Stephan Weidinger, MD, PhD

5-Year ADlong Data on Lebrikizumab for Eczema, With Stephan Weidinger, MD, PhD

Todays Updates

Phase 2 ACUITY Analysis Shows Privosegtor Associated With Smaller Early NfL and GFAP Increases in Acute Optic Neuritis Isabella Ciccone, MPH

New biomarker data showed smaller post-onset increases in plasma neurofilament light chain and glial fibrillary acidic protein with privosegtor added to steroids in patients with acute optic neuritis.

CORE-VNS Study Shows Sustained Seizure Reduction With VNS Therapy at 36 Months Louie Pasculli

The 36-month CORE-VNS study findings showed sustained seizure reduction, improved quality of life, and reduced seizure-related hospitalizations among people with drug-resistant epilepsy receiving vagus nerve stimulation therapy.

The Expanding Role of Blood-Based Biomarkers in MS Care Louie Pasculli, Terrie Livingston, PharmD

Terry Livingston, PharmD, vice president of medical affairs at Octave Bioscience, discussed the evolving role of blood-based biomarkers in multiple sclerosis care.

Matching CKD Education to Patient Readiness for Home Dialysis, With Christopher Chan, MD

Matching CKD Education to Patient Readiness for Home Dialysis, With Christopher Chan, MD

Upacicalcet Lowers PTH in Secondary Hyperparathyroidism on Hemodialysis

Upacicalcet Lowers PTH in Secondary Hyperparathyroidism on Hemodialysis

Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial

Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial

Todays Updates

Phase 2 ACUITY Analysis Shows Privosegtor Associated With Smaller Early NfL and GFAP Increases in Acute Optic Neuritis Isabella Ciccone, MPH

New biomarker data showed smaller post-onset increases in plasma neurofilament light chain and glial fibrillary acidic protein with privosegtor added to steroids in patients with acute optic neuritis.

CORE-VNS Study Shows Sustained Seizure Reduction With VNS Therapy at 36 Months Louie Pasculli

The 36-month CORE-VNS study findings showed sustained seizure reduction, improved quality of life, and reduced seizure-related hospitalizations among people with drug-resistant epilepsy receiving vagus nerve stimulation therapy.

The Expanding Role of Blood-Based Biomarkers in MS Care Louie Pasculli, Terrie Livingston, PharmD

Terry Livingston, PharmD, vice president of medical affairs at Octave Bioscience, discussed the evolving role of blood-based biomarkers in multiple sclerosis care.

Matching CKD Education to Patient Readiness for Home Dialysis, With Christopher Chan, MD

Matching CKD Education to Patient Readiness for Home Dialysis, With Christopher Chan, MD

Upacicalcet Lowers PTH in Secondary Hyperparathyroidism on Hemodialysis

Upacicalcet Lowers PTH in Secondary Hyperparathyroidism on Hemodialysis

Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial

Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial

Latest News

The HCPFive: Top News for Healthcare Providers from the Week of 10/18

Lutikizumab Improves HS Pain, Flares in Phase 3 INTREPID Study

Shannon C. Trotter, DO, FAOCD, discusses immunotherapy in advanced cutaneous squamous cell carcinoma and why dermatologists should stay involved.

Nonsurgical Skin Cancer Care and New Approvals, With Todd Schlesinger, MD

Both doses of the anti-ILT7 antibody daxdilimab reduced CLASI-A scores vs placebo at week 24 in moderate-to-severe, treatment-refractory discoid lupus.

5-Year ADlong Data on Lebrikizumab for Eczema, With Stephan Weidinger, MD, PhD

News All Time

Q&A: Insights on New Lebrikizumab Findings for Hand and Foot Atopic Dermatitis

Q&A: Insights on New Lebrikizumab Findings for Hand and Foot Atopic Dermatitis

Nemolizumab Safety, Real-World Use in AD, With Matthias Augustin, MD Matthias Augustin, MD

An ARCADIA investigator says patients in practice match the 3-year trial results and outlines next steps for IL-31 research.

No Signal for Birth Defects in Dupilumab Pregnancy Registry, With Tina Chambers, PhD, MPH Christina Chambers, PhD, MPH

Chambers discusses final results from a 7-year dupilumab pregnancy registry showing no evidence of increased risk for major birth defects or other outcomes.

Phase 3 Ritlecitinib Results in Vitiligo, With Iltefat Hamzavi, MD Iltefat Hamzavi, MD

Iltefat H. Hamzavi, MD, discusses phase 3 Tranquillo data showing higher facial and total body repigmentation with ritlecitinib in vitiligo.

Is Hidradenitis Suppurativa Underdiagnosed in Male Patients?

Is Hidradenitis Suppurativa Underdiagnosed in Male Patients?

Q&A: Comorbidity Screening and Biologic Timing in HS, With Jennifer Hsiao, MD

Q&A: Comorbidity Screening and Biologic Timing in HS, With Jennifer Hsiao, MD

Nemolizumab Sustains AD Response at 3 Years, With Matthias Augustin, MD Matthias Augustin, MD

Up to 91% of patients reached EASI-75 at week 152 in the ARCADIA LTE, with consistent safety and gains in itch and quality of life.

Denifanstat Sustains Acne Improvement Through 52 Weeks in Phase 3 Extension

Denifanstat Sustains Acne Improvement Through 52 Weeks in Phase 3 Extension

Upadacitinib Feasible for Palmoplantar Pustulosis: David Gleeson, BM BCH David Gleeson, BM BCH

Gleeson discusses JAKPPPOT data showing the therapy met all feasibility thresholds with a markedly larger response than historic placebo in PPP.

Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years

Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

Navigating Corticosteroid Stewardship in Dermatology, With Kristina Derrick, MD Kristina Derrick, MD

Kristina Derrick, MD, explains how prior authorization and cost limit steroid-sparing care, and how dermatologists can document corticosteroid exposure.

Denifanstat Sustains Acne Control Through 52 Weeks, With Neal Bhatia, MD Neal Bhatia, MD

Bhatia discusses 52-week extension data showing denifanstat sustained acne control with a favorable long-term safety profile, presented at EADV 2026.

Moving Corticosteroid Stewardship into Policy, With Killian Lozach, MBA Killian Lozach, MBA

Lozach outlines how the Corticosteroid Stewardship Alliance plans to bring clinician data and adverse event costs to payers and lawmakers.

Remibrutinib Receives FDA Approval for Symptomatic Dermographism

Remibrutinib Receives FDA Approval for Symptomatic Dermographism

Recommended News For You

Researchers discuss HER2-low and HER2-zero in breast cancer

A new device enhances liquid biopsy.

Tissue-Free ctDNA Strongly Prognostic of Recurrence in TNBC

Advanced breast cancer patients living longer thanks to improvements in treatment and care

Study Linking Fruits, Veggies to Lung Cancer Raises Eyebrows

Admissions, medical schools, costs, and eligibility requirements information for FNB Head and Neck Oncology.

High CLL Remission Seen With First-Line Triplet Regimen

Recommended Articles For You

Oncolytic Vaccinia Virus Immunotherapy: A New Frontier in GI Cancer Treatment 

Unlocking the Potential of Elotuzumab: A Promising New Cancer Treatment 

Altered Tumor–Host Tissue Mechanics During Progressive Cancer Growth 

Cancer Susceptibility Landscapes in Precision Oncology 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Toxic fungus from King Tutankhamun's tomb yields cancer-fighting compounds—new study

2.

Study shows virtual reality headsets may help ease cancer pain

3.

Nationwide Epinephrine Recall; FBI's Fauci Probe; Bruce Campbell's Cancer

4.

Spouses of Cancer Patients May Be at Increased Risk of Suicide

5.

Study finds 81% of cancer cures touted by TikTok videos are fake

1.

Personalized Survivorship Navigation in Precision Cancer Care

2.

The Essential Guide to Understanding Fibrinogen and Its Role in Blood Clotting 

3.

Mechanistic Depth and Clinical Impact of Rusfertide, Onyvide, IV Avastin, and Pemfexy

4.

Digital Oncology: How Remote Monitoring and Mobile Health Are Transforming Cancer Care

5.

Ethics of Experimental Oncology: Case Study on Autonomy, Consent & Decision-Making

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

How Nutrition Can Support Patients During Cancer Care

2.

Virtual Case Study on Deep Vein Thrombosis (DVT) - An Initiative by Hidoc Dr.

3.

Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC

4.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation

5.

What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot